Pomegra
EpiCrispr Biotechnologies closed a $90 million oversubscribed Series C on August 11 to fund pivotal-track preparations for EPI-321, its one-time epigenetic silencing therapy for facioscapulohumeral muscular dystrophy.
- $90M Series C co-led by Octagon Capital and Janus Henderson; syndicate spans crossovers, strategics, and family office capital
- EPI-321 silences the DUX4 gene via AAV delivery; Phase 1/2 patients showed lean muscle gains at six months post-infusion
- Proceeds fund pivotal study preparations, manufacturing scale-up, and expansion of the company's GEMS platform
Lead
South San Francisco-based EpiCrispr Biotechnologies raised $90 million in an oversubscribed Series C announced August 11, 2026, co-led by Octagon Capital and Janus Henderson Investors. The round drew participation from Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, abrdn Inc., Angelini Ventures, and Readout Capital. The capital will fund preparations for pivotal studies of EPI-321, the company's lead candidate for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle disease with no approved treatment that affects an estimated 870,000 people worldwide.
What Is EPI-321?
EPI-321 is a one-time, intravenously administered therapy that silences DUX4, the aberrantly activated gene that drives muscle degeneration in FSHD. Unlike approaches that cut or rewrite DNA, EPI-321 uses epigenetic editing - deploying CRISPR machinery to modify gene expression without altering the underlying genetic sequence. Delivered via a clinically established adeno-associated virus (AAV) vector, the therapy acts on the root cause of the disease rather than its downstream symptoms.
The mechanism occupies a specific niche between traditional gene replacement therapy and permanent DNA editing. In FSHD, the problem is not a missing gene but a misexpressed one - DUX4 activates in adult muscle cells where it should stay silent. Silencing, not replacement, is the correct therapeutic logic here. EpiCrispr calls its underlying delivery system the Gene Expression Modulation System (GEMS).
What Does Early Clinical Data Show?
EPI-321 entered first-in-human testing after FDA cleared its IND application, becoming the first epigenetic therapy for a neuromuscular condition to reach the clinic. In the ongoing Phase 1/2 study, three patients at the lower dose cohort averaged roughly 0.8 pounds of lean muscle gain at six months post-infusion - a range of approximately 0.5 to 1.3 pounds across the three. No safety signals have been disclosed that disrupted trial progress. The favorable safety read combined with a directional efficacy signal is what carries this round.
Those numbers are modest in absolute terms. But for a disease that has resisted every therapeutic attempt to date, even a consistent directional effect from a single IV dose is commercially meaningful context for a pivotal study discussion with FDA.
Strategic Context
EpiCrispr previously raised $68 million in a Series B, bringing total disclosed funding to roughly $158 million before this close. The Series C at $90 million signals a funding trajectory that has stepped up sharply as the company crosses into pivotal-enabling work. Post-money valuation was not disclosed.
The syndicate composition tells a clear story about where the company is headed. Crossover participation from Janus Henderson alongside strategic money from Sanofi Ventures and family office capital from Duquesne Family Office suggests investors across risk appetite are pricing in a public market event within the next two to three years. Anran Li of Octagon Capital will join the board as part of the transaction.
Why Does Epigenetic Editing Draw This Level of Capital?
The appeal is partly scientific and partly regulatory positioning. Epigenetic edits modify how genes are read, not the DNA itself, which avoids permanent alteration of the genome. For patient populations that may be skeptical of irreversible changes - and for a regulatory environment still forming its framework around novel editing modalities - that distinction carries weight. Whether it translates to meaningfully faster FDA pathways remains unresolved.
The approach is also theoretically applicable across multiple diseases driven by aberrant gene expression, not just FSHD. EpiCrispr's GEMS platform is designed to be programmable toward other targets, which gives the company a pipeline story beyond a single indication. Investors in early gene editing platforms have learned the hard way that a single-asset bet on a rare disease is a fragile thesis.
Outlook
EpiCrispr exits this financing with enough runway to complete pivotal-enabling work on EPI-321 and advance the GEMS platform toward additional targets. The next significant clinical read - dose escalation cohorts from the ongoing Phase 1/2 - will determine whether the muscle-gain signal holds at higher doses and whether a durable safety profile is maintained. If it does, the company moves into pivotal study design and FDA alignment. FSHD remains a wide-open field with no approved competitor, which simplifies the commercial logic but also means there is no established regulatory precedent to follow. The first approved epigenetic medicine for a neuromuscular disease would be a new category; the path to get there still has meaningful uncertainty in it.
